^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

RG6538

i
Other names: RG6538, P-BCMA-ALLO1, allogeneic chimeric antigen receptor T cell therapies, PBCMAALLO1, RG-6538, P BCMA ALLO1, RG 6538
Associations
Trials
Company:
J&J, Poseida Therap, Roche
Drug class:
BCMA-targeted CAR-T immunotherapy
Related drugs:
Associations
Trials
9ms
P-BCMA-ALLO1-001: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (clinicaltrials.gov)
P1, N=231, Recruiting, Poseida Therapeutics, Inc. | N=135 --> 231 | Trial completion date: Mar 2040 --> Dec 2039 | Trial primary completion date: Jun 2025 --> Dec 2027
Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
RG6538 • rimiducid (AP1903)
1year
Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM) (ASH 2023)
We are currently dosing patients in arm S (Cyclophosphamide (Cy) 300 mg/m2 + Fludarabine (Flu) 30 mg/m2 X 3 days), arm P1 (Cy 500 mg/m2 + Flu 30 mg/m2 X 3 days), arm P2 (Cy 1,000 mg/m2 + Flu 30 mg/m2 X 3 days) and arm C (multiple P-BCMA-ALLO1 doses following Cy 300 mg/m2 + Flu 30 mg/m2 X 3 days). P-BCMA-ALLO1 is a non-viral transposon-generated allogeneic "off-the-shelf" CAR-T that is rapidly available for administration and well tolerated in a heavily pretreated RRMM patient population with minimal CRS/ICANS risk. Updated results including safety, preliminary efficacy, and selected biomarkers will be presented at the American Society of Hematology 2023 meeting.
Clinical • CAR T-Cell Therapy • IO biomarker
|
B2M (Beta-2-microglobulin)
|
cyclophosphamide • fludarabine IV • RG6538
almost3years
Memory Phenotype in Allogeneic Anti-BCMA CAR-T Cell Therapy (P-BCMA-ALLO1) Correlates with In Vivo Tumor Control (ASH 2021)
Figure 1: Memory composition of P-BCMA-ALLO1 research products. P-BCMA-ALLO1 consists mostly of stem cell memory (T scm ) and central memory (T cm ) T cells that are CD62L + as opposed to effector memory (T em ) and effector (T eff ) T cells.
Preclinical • CAR T-Cell Therapy • IO biomarker
|
IL7R (Interleukin 7 Receptor) • CCR7 (Chemokine (C-C motif) receptor 7) • CD27 (CD27 Molecule)
|
RG6538